IP Library › Granted Patent US 7,780,989
Granted Patent B2
US 7,780,989 · App. 10/521,617 · Granted Aug 24, 2010

Process for the preparation of crystalline nano-particle dispersions

Assignee: AstraZeneca AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,780,989
App. No.
10/521,617
Granted
Aug 24, 2010
Kind
B2
Abstract

A process for the preparation of a dispersion of crystalline nanoparticles in an aqueous medium is disclosed. Specifically, a first solution comprising a substantially water-insoluble substance in a water-miscible organic solvent is rapid mixed with an aqueous phase comprising water, and optionally a stabilizer, to form a dispersion of amorphous particles. The dispersion of amorphous particles is then sonicated for a sufficient period to form crystalline nanoparticles of the substantially water-insoluble substance. The process provides nanocrystals with a mean hydrodynamic diameter of less than 1 micron, particularly less than 300 nm, and is particularly useful for the preparation of nanocrystalline dispersions of pharmaceutical substances.

Claims (21)

1. A process for the preparation of a dispersion of nano-crystalline particles in an aqueous medium, the process comprising the steps:

(a) combining in less than 30 seconds a first solution and an aqueous phase under rapid mixing to form a dispersion of amorphous particles, wherein:

(i) the first solution comprises a substantially water-insoluble substance in a water-miscible organic solvent, and

(ii) the aqueous phase comprises water and optionally a stabilizer,

(b) sonicating the dispersion of amorphous particles for at least 10 minutes to form nanocrystalline particles having a mean particle size of from 10 to 200 nm of the substantially water-insoluble substance; and

(c) optionally removing the water-miscible organic solvent.

2. The process according to claim 1 , wherein the substantially water-insoluble substance is a pharmacologically active compound.

3. The process according to claim 1 , wherein the concentration of the substantially water-insoluble substance in the aqueous medium following step (a) is 10 mM or less.

4. The process according to claim 3 , wherein the concentration of the substantially water-insoluble substance in the combined solution and aqueous phase following step (a) is from 0.5 to 3 mM.

5. The process according to claim 1 , wherein the aqueous phase contains a stabiliser.

6. The process according to claim 5 , wherein the stabiliser comprises a polymeric dispersant and an amphiphilic surfactant.

7. The process according to claim 6 , wherein the amphiphilic surfactant is an anionic, cationic, or non-ionic surfactant.

8. The process according to claim 7 , wherein the polymeric dispersant is polyvinylpyrrolidone and the anionic surfactant is sodium dodecyl sulfate.

9. The process according to claim 6 , wherein the amphiphilic surfactant is at a concentration below the critical association concentration for the amphiphilic surfactant and polymeric dispersant.

10. The process according to claim 1 , wherein rapid mixing comprises using sonication during the combination.

11. The process according to claim 1 , wherein the first solution is added to the aqueous phase.

12. The process according to claim 1 , wherein the dispersion of amorphous particles is sonicated at a temperature below 50° C.

13. The process according to claim 1 , further comprising isolating the nano-crystalline particles after formation of the nanocrystalline particles or after removal of the water-miscible organic solvent.

14. The process according to claim 1 , wherein the dispersion of amorphous particles is sonicated for 20 to 100 minutes.

15. The process according to claim 1 . wherein the first solution is added to the aqueous phase, wherein the aqueous phase comprises water. a polymeric dispersant, and an amphiphilic surfactant, and the concentration of the substantially water-insoluble substance in the combined first solution and aqueous phase following step (a) is 10mM or less.

16. The process according to claim 15 , wherein the first solution and aqueous phase are combined by rapid mixing using sonication during the combination.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2005
From: SKANTZE, TOMMY URBAN; LINDFORS, PER LENNART; FORSSEN, SARA
To: ASTRAZENECA AB
Reel/Frame 016695/0055 →
Priority Claims (1)
GB 0216700.5 · Jul 18, 2002 · national
Continuity (1)
Related Publication 20050202092A1 · Sep 15, 2005